Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Simple blood test may spot Alzheimer's early

NCT ID NCT01315639

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether measuring certain proteins in the blood (amyloid peptides) can help diagnose Alzheimer's disease or predict its progression. Over 1,000 older adults with mild cognitive impairment or Alzheimer's were followed for two years. Researchers compared blood levels of these proteins between those whose condition worsened and those who remained stable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to help diagnose Alzheimer's disease earlier or predict how fast it will progress.
What could go wrong
This is an observational study, not a treatment trial. The blood test may not be accurate enough for routine use, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,067 people

The number who actually took part.

Started

Sep 2010

Finished

Mar 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: MCI group : * ≥ 70 years * MCI diagnosis : New criteria (Petersen, PORTET\*) 1. cognitive complaint from the patient, family, or both, 2. report by the subject or reporter of a decline in cognitive or functional performance, relative to previous abilities, 3. cognitive disorders evidenced by clinical evaluation: impairment in memory or another cognitive domain, 4. cognitive impairment without any repercussion on daily life, even if the subject reports difficulties concerning complex daily activities, 5. no dementia * Having signed an informed consent form * Fluent in French AD group : * ≥ 45 years * AD diagnosis (DSM IV-TR et NINCDS-ADRDA) * Mild to moderate (MMSE \> 15) * Having signed an informed consent form * Caregiver/informant to provide information on patient Exclusion Criteria: * Normal cognitive function * Major depression (according to the DSMIV-TR or MINI or Geriatric depression Scale\> 20/30) * Genetic form of AD (genetic mutation known) * All other diseases that could interfere with cognitive assessment (Epilepsy, Parkinson's disease, schizophrenia, other dementia) * Major sensory deficits that could interfere with cognitive assessment (visual and auditory) * Diseases involving the short-term survival (advanced cancer, unstable heart disease, severe hepatic/respiratory/renal failure) * Contraindication for MRI, for lumbar puncture (i.e. anticoagulant agents) * Use of any experimental agent for the duration of the study * Participation to other biomedical research that could interfere with principal objective of the study * For MCI patient, use of IchE or memantine medication before inclusion * Less than 4 years of education * Illiteracy, is unable to count or to read * Pregnant women * Non health insurance affiliation * Private subjects of freedom by legal or administrative decision * Contraindication for MRI examination: * Claustrophobic subject * Carrying a cardiac pacemaker * Presence of any ferromagnetic metallic implants or foreign bodies (carrying an internal electrical/magnetic device, carrying a valvular prosthesis) * Carrying a ventricular valvular Exclusion criteria specific to the lumbar puncture: • Taking anticoagulant agents

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia Memory Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • APHP, Hôpital Broca

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.